← The Wire
AZNNYSE
ASTRAZENECA PLC
Pharmaceutical Preparations · X0 · CIK 901832
AstraZeneca PLC develops, manufactures, and sells prescription medicines, including biologics and vaccines
🔥 High media attention
$277.22B
Market cap
$190.95
Last close
+1.4%
1D
+8.2%
5D
1.6M
Volume
Price · last 39 sessions+4.1%
May 4L $174.93 · H $190.95Jun 29
883
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
11-KFORM 11-KJun 29, 20266-KENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURSJun 29, 20266-KDATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBCJun 29, 20266-KTRUQAP APPROVED IN US FOR PROSTATE CANCERJun 15, 20266-KADMISSION OF FURTHER SECURITIES TO TRADINGJun 1, 20266-KTOTAL VOTING RIGHTSJun 1, 20266-KIMFINZI APPROVED IN US FOR EARLY BLADDER CANCERMay 29, 20266-KUS FDA DECISION DATE ON CAMIZESTRANT EXTENDEDMay 27, 20266-KDATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BCMay 26, 20266-KENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURSMay 26, 20266-KCAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EUMay 26, 20266-KDIRECTOR/PDMR SHAREHOLDINGMay 18, 20266-KBAXFENDY APPROVED IN THE US FOR HYPERTENSIONMay 18, 20266-KENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGSMay 18, 20266-KIMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCERMay 14, 20266-KTOTAL VOTING RIGHTS AND ADMISSION OF SHARESMay 1, 20266-KFDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCERMay 1, 20266-KFDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCERMay 1, 20266-K1ST QUARTER RESULTSApr 29, 20266-KBREZTRI APPROVED IN THE US FOR ASTHMAApr 28, 20266-KSAPHNELO SELF-ADMINISTRATION APPROVED IN THE USApr 27, 20266-KDIRECTORATE CHANGEApr 23, 20266-KI CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINTApr 21, 20266-KTHIRD TOZORAKIMAB POSITIVE PHASE III IN COPDApr 20, 20266-KRESULT OF AGMApr 9, 20266-KIMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCERApr 2, 20266-KTOTAL VOTING RIGHTS AND ADMISSION OF SHARESApr 1, 20266-KEFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTSMar 31, 20266-KTOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTSMar 27, 20266-KNOTIFICATION OF ADMISSION OF SHARESMar 20, 20266-KIMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCERMar 16, 20266-KNOTICE OF AGMMar 10, 20266-KFORM 6-KMar 10, 20266-KDIRECTOR/PDMR SHAREHOLDINGMar 6, 20266-KDIRECTOR/PDMR SHAREHOLDINGMar 6, 20266-KDIRECTOR/PDMR SHAREHOLDINGMar 6, 20266-KFORM 6-KMar 2, 20266-KTOTAL VOTING RIGHTSMar 2, 20266-KASTRAZENECA PRICES A $2BN BOND OFFERINGFeb 26, 20266-KFILING OF FORM 20-F WITH SECFeb 25, 202620-F20-FFeb 24, 20266-KFORM 6-KFeb 24, 20266-KANNUAL FINANCIAL REPORTFeb 24, 20266-KDIRECTORATE CHANGEFeb 24, 20266-KFIXED-DURATION CALQUENCE COMBO APPROVED IN USFeb 20, 20266-KFINAL RESULTSFeb 10, 2026SC 13D/ASC 13D/AFeb 6, 20266-KUPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATIONFeb 3, 20266-KTOTAL VOTING RIGHTSFeb 2, 20266-KIMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCERFeb 2, 20266-KASTRAZENECA BEGINS TRADING ON NYSEFeb 2, 20266-KASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPCJan 30, 20266-KASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030Jan 29, 20266-KASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSEJan 20, 20266-KAZN NEW HEAD OF INVESTOR RELATIONS JORIS SILONJan 8, 20266-KTOTAL VOTING RIGHTSJan 2, 20266-KDIRECTOR/PDMR SHAREHOLDINGDec 22, 20256-KENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BCDec 22, 20256-KUPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIBDec 22, 20256-KDIRECTOR/PDMR SHAREHOLDINGDec 19, 20256-KSUBCUTANEOUS SAPHNELO APPROVED IN EUDec 16, 20256-KENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BCDec 16, 20256-KHOLDING(S) IN COMPANYDec 4, 20256-KBLOCK LISTING INTERIM REVIEWDec 1, 20256-KTOTAL VOTING RIGHTSDec 1, 20256-KIMFINZI APPROVED IN US FOR EARLY GASTRIC CANCERNov 26, 20256-KASTRAZENECA MANUFACTURING INVESTMENT IN MARYLANDNov 24, 20256-KKOSELUGO (SELUMETINIB) APPROVED IN THE USNov 20, 20256-KHOLDING(S) IN COMPANYNov 17, 20256-KDIRECTOR/PDMR SHAREHOLDINGNov 14, 20256-KDIRECTOR/PDMR SHAREHOLDINGNov 10, 20256-K9M AND Q3 2025 RESULTSNov 6, 20256-KRESULT OF GENERAL MEETINGNov 3, 20256-KTOTAL VOTING RIGHTSNov 3, 20256-KFORM 6-KNov 3, 20256-KDIRECTOR DECLARATIONOct 28, 20256-KKOSELUGO (SELUMETINIB) APPROVED IN THE EUOct 28, 20256-KTEZSPIRE APPROVED IN EU FOR CRSWNPOct 22, 20256-KUS FDA APPROVES TEZSPIRE IN CRSWNPOct 20, 20256-KPOSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELOOct 20, 2025
In the News
🔥 High media attentionCoverage (30d): 5 reputable articles · skews ▲ positive.
Financial TimesAstraZeneca advances weight-loss pill to take aim at obesity leaders22d agoCNBCAstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success25d agoFinancial TimesAstraZeneca chief warns group could withhold new drugs in Europe25d agoMarketWatchAstraZeneca falls Monday, underperforms market29d agoInvestor's Business DailyAstraZeneca Scores In Liver Cancer On Its Path To $40 Billion In Oncology Sales29d agoFinancial TimesUS regulator delays decision on AstraZeneca cancer drug1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance